Approximately 50% of patients with advanced prostate cancer have elevated levels of serum IL-6 in comparison with men with normal prostates, benign prostatic hyperplasia, prostatitis and localised disease (Twillie et al, 1995; Drachenberg et al, 1999). The gene discussed is IL6; the disease is benign prostatic hyperplasia.